TAKE Solutions Ltd.
has strengthened its Drug Safety and Pharmacovigilance solutions and services offering to cater to the growing needs of Pharma Emerging nations. The company has partnered with
MENE Research
wherein they together will cater to the Drug Safety requirements of Middle East, Europe, and West Asian countries.
Both the companies together will work towards providing the life science industry with strategy, solutions and services for drug safety operations thus ensuring global regulatory compliance and effective patient safety methodologies is followed. This partnership becomes strong by the fact that TAKE already has to its credit creating a framewokr—SafetyReady—along with a thought leadership in Drug Safety and Pharmacovigilance segments and Mene Research’s regional experience in Middle East, Europe, West Asia, etc.
TAKE Solutions extended Drug Safety and Pharmacovigilance Service Offerings with recent launch of SafetyReady for Oracle Argus Safety Suite Customers. Read
more
.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.